Evidence map›Paper›PMID 42393415›Full record

ArticleAnnals of surgical oncology2026

The Impact of Tumor Size on Therapeutic Decision-Making for Upper Tract Urothelial Carcinoma: A Large-Scale Population Analysis.

Peng Hong, Zenan Liu, Hongxian Zhang, Jian Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peng Hong *Department of Urology, Peking University Third Hospital, No. 49 North Garden Rd., Haidian District, Beijing, 100191, China.
Zenan Liu *Department of Urology, Peking University Third Hospital, No. 49 North Garden Rd., Haidian District, Beijing, 100191, China.
Hongxian ZhangDepartment of Urology, Peking University Third Hospital, No. 49 North Garden Rd., Haidian District, Beijing, 100191, China. zwl2006@163.com.
Jian LuDepartment of Urology, Peking University Third Hospital, No. 49 North Garden Rd., Haidian District, Beijing, 100191, China. lujian@bjmu.edu.cn.

Funding

Clinical Cohort Construction Program of Peking University Third Hospital BYSYDL2022018Natural Science Foundation of Beijing Municipalit L212051
6 · The paper itself

Abstract

purposeThis study was designed to clarify the impact of tumor size on risk stratification in UTUC and to evaluate the feasibility and effectiveness of using 2 cm as a cutoff value for risk stratification.

methodsUsing data from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2021), we identified patients with nonmetastatic UTUC who underwent radical nephroureterectomy (RNU). Overall survival (OS) and cancer-specific survival (CSS) curves were generated by using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to identify predictors of OS and CSS. Univariate and multivariate logistic regression models were applied to assess predictors of adverse pathological features.

resultsA total of 10,607 UTUC patients treated with RNU were included, comprising 7503 (70.7%) with renal pelvic UC and 3104 (29.3%) with ureteral UC. Tumor size ≥2.0 cm was independently associated with muscle-invasive disease (P < 0.001) and nonorgan-confined tumors (P < 0.001), but not with lymph node metastasis (P = 0.181). Tumor size ≥ 2.0 cm was independently associated with OS (P = 0.007) but not with CSS (P = 0.236). No significant difference in risk stratification ability was observed between a tumor size cutoff of 2.0 cm and those of 1.5 cm or 3.0 cm.

conclusionsA 2-cm cutoff is a reasonable threshold for risk stratification in UTUC. Tumors larger than 2 cm are associated with a significantly increased risk of muscle layer invasion, extraorgan extension, and lymph node metastasis.

Indexed as

Carcinoma, Transitional CellClinical Decision-MakingKidney NeoplasmsNephroureterectomyUreteral NeoplasmsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSEER ProgramSurvival RateTumor Burden

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.